Current Alzheimer Research (Volume 23 - Issue 2)

Current Perspectives on Oxytocin and Alzheimer’s Disease-Related Symptoms

2026-04-16

Alzheimer’s Disease (AD) is a neurodegenerative disorder accounting for 60-80% of dementia cases globally. Several risk factors are associated with increased AD onset, including genetics, physical activity, and varying levels of social interaction. Extensive research has explored potential treatments for AD, among which oxytocin (OX) has shown beneficial effects on memory-related neurological processes. OX has been suggested to modulate neuroplasticity within the hippocampus in rat and mouse AD models. Further studies indicate that intranasal administration of OX may lead to significant improvements in memory and cognition. In addition, a non-peptide agonistic analogue, LIT-001, has been investigated. This review aims to provide insight into the potential of OX as a therapeutic target for AD and to explore alternatives that activate similar cellular signaling pathways.

The Role of Lipoprotein and Gut Microbiome in Alzheimer's Disease: A Review of Novel Findings and Potential Applications

2026-04-16

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is inadequately comprehended, with hypotheses implicating amyloid-β, tau pathology, mitochondrial dysfunction, and epigenetic factors. Recent research underscores the significance of lipoproteins and the gut microbiota in the etiology of AD. Apolipoprotein E (ApoE), particularly the E4 subtype, emerges as a key genetic risk factor, influencing oxidative stress, synaptic defects, glucose metabolism, and amyloid-β clearance. Lipoprotein receptors, such as LRP-1, also influence the integrity of the blood-brain barrier, indicating potential for therapeutic applications. Novel therapies targeting lipoproteins, such as ALZ-801 and IDOL inhibitors, show promise in preclinical and clinical trials. Concurrently, the gut microbiome’s impact on AD is increasingly recognized. Dysbiosis correlates with inflammation, mitochondrial oxidative stress, impaired autophagy, and neurotransmitter imbalances. Gut-derived metabolites, including phenylalanine and isoleucine, promote Th1 cell activation and microglial dysfunction, exacerbating AD pathology. Interventions, like probiotics, GV-971, and polyphenols, demonstrate efficacy in restoring microbial balance and mitigating cognitive decline. Crucially, bidirectional interactions between lipoproteins and the gut microbiome are implicated in AD. ApoE genotypes influence gut microbial composition, while microbiota- derived short-chain fatty acids and endotoxins modulate lipid metabolism and neuroinflammation. These interactions, mediated via the gut-brain axis, highlight novel therapeutic avenues. Current FDA-approved AD drugs face limitations in efficacy and side effects, underscoring the need for innovative strategies targeting lipoprotein-gut microbiome crosstalk. Integrating insights into lipoprotein biology and gut microbiota dynamics may offer transformative potential for AD treatment, emphasizing combinatorial approaches to modulate these interconnected pathways. Further research is warranted to elucidate mechanistic links and translate preclinical findings into clinical applications.

Unlocking Neuroprotection: Potassium Channel Openers in Alzheimer's Disease

2026-04-16

Alzheimer's disease is a neurodegenerative disorder characterized by impairments in cognitive functions such as thinking, behavior, and memory. The major pathological abnormalities associated with the disease include the formation of neurofibrillary tangles and amyloid plaques, which further cause neuroinflammation and nerve cell death. Currently, treatments for the disease focus on symptomatic management rather than addressing the root cause of neurological changes. Therefore, the current status of therapy highlights the need for more effective therapeutic substances that can either prevent abnormal deposition or slow neurodegeneration to preserve nerve cells. In this respect, ATP-sensitive potassium channel openers may have a potential role in prevention and protection. The present article focuses on several cellular mechanisms of this class, including the limitation of neuronal excitability, modulation of neurotransmitter release, prevention of aberrant protein buildup, reduction of excessive calcium influx, reduction of reactive oxygen species levels, and reduction of microglial activation.

The Role of Microglial Cells and Cytokine Modulation in Alzheimer’s Disease: A Neuroinflammatory Perspective

2026-04-16

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by abnormalities in protein metabolism leading to the accumulation of extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles (hyperphosphorylated tau protein). While these pathological constructs have held significant attention for decades, emerging evidence highlights the understanding of neuroinflammation (notably involving microglia, and cytokine signaling) as a critical initial event with respect to the inception and progression of AD. This review discusses the dynamic and dualistic effects of immune response in AD based on the relationship between neuroinflammatory processes and classical neuropathological characteristics. Microglia are ubiquitous immune cells in the central nervous system responsible for maintaining homeostasis as the brain's \"housekeepers\" by removing cellular debris, pruning synapses, and monitoring cell interactions. However, microglia in AD function produce a chronically activated phenotype that elicits neurotoxicity, impairs synaptic functioning, and is are protracted source of neuroinflammation. The appearance of disease-associated microglia (DAM) may illustrate complexities of TREM2 signaling for the anabolism of Aβ clearance and the modulation of inflammatory systems. Cytokine imbalance - higher expression of pro-inflammatory (e.g., IL-1β, TNF-α) and lower expression of antiinflammatory (e.g., IL-10, TGF-β) - adds to a self-perpetuating inflammatory loop that exacerbates Aβ and tau pathology, brain-blood barrier permeability, and peripheral-CNS immune communications. The mechanisms of an inflammatory event may drive brain tau hyperphosphorylation, tau propagation, along with other pathophysiological neurodegenerative features of traumatic brain injury and Alzheimer's disease. While examples of therapies targeting microglia and their cytokine activity are actively being explored, clinical efforts have been mixed. Neuroimaging development (e.g., TSPO-PET), cytokine collection and compositional approaches, and application of single-cell transcriptomics are providing new ways of thinking about complex neuroimmunology. Exploring, informing, and defining the timing, context, and variations of neuroinflammatory responses will be ultimately needed to create effective, targeted therapies for Alzheimer's disease (AD).

miRNAs: Promising Biomarkers for Alzheimer's Diagnosis and Treatment

2026-04-16

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-beta (Aβ) plaque deposition, neurofibrillary tangles of hyperphosphorylated tau protein, and chronic neuroinflammation, leading to synaptic dysfunction and cognitive decline. Current diagnostic methods rely on clinical symptoms and limited biomarkers, while available treatments only provide symptomatic relief without halting disease progression. MicroRNAs (miRNAs), small non-coding RNAs of 19-22 nucleotides, have emerged as crucial regulators of gene expression through post-transcriptional mechanisms and show distinct dysregulation patterns in AD patients' blood, cerebrospinal fluid (CSF), and brain tissues. Key miRNAs such as miR-132, miR-146a, miR-34a, and miR-125b demonstrate consistent alterations in expression levels, correlating with disease progression and offering potential as non-invasive diagnostic tools. This review comprehensively examines the dual role of miRNAs as diagnostic biomarkers and therapeutic targets for AD. We also provide an analysis of specific miRNA signatures in different biofluids (plasma, serum, CSF) and brain regions that correlate with disease stages, highlighting their potential for early and non-invasive diagnosis. Therapeutically, miRNAs modulate multiple AD-related pathways, including neuroinflammation via NF-κB signaling, Aβ production through BACE1 inhibition, and tau phosphorylation via GSK3β regulation. miRNAs also influence synaptic plasticity, mitochondrial function, and autophagy, presenting multifaceted opportunities for intervention. However, challenges, including miRNA heterogeneity, stability, and targeted delivery, remain critical impediments. Advances in nanocarriers, exosomal miRNAs, and viral vectors show promise in overcoming these obstacles, enabling precise miRNA modulation. In addition, we underscore the need for standardized protocols, further validation in clinical cohorts, and the development of cost-effective detection methods to translate miRNA-based approaches into practical diagnostics and therapies. By integrating miRNA biomarkers with existing diagnostic tools and exploring combinatorial therapeutic strategies, researchers can harness the potential of miRNAs to revolutionize AD intervention, paving the way for early detection and effective treatment of this devastating disease.

Improving Quality of Life in Dementia through Tailored Interventions: A Systematic Review from Saudi Arabia

2026-04-16

Introduction: Quality of life (QoL) in dementia care can be enhanced through nonpharmacological interventions. This systematic review and meta-analysis aimed to evaluate the effectiveness of such interventions across demographic groups in Saudi Arabia.

Methods: A systematic search identified 11 studies assessing sensory stimulation, mindful walking, functional independence, caregiver support, and public awareness interventions. Data were extracted on study design, population, and outcome measures. Three outcome studies were narratively synthesized.

Results: Sensory stimulation interventions (n = 62) showed the strongest behavioral improvements, with a large effect size (Hedges’ g = –2.03). Data from other studies were insufficient for quantitative pooling, and no formal meta-regression or heterogeneity analyses were conducted.

Discussion: Findings suggest that behavioral and psychological interventions tailored to older adults yield the most significant QoL benefits. Caregiver support and awareness programs offer important supplementary benefits, although limited data restrict broader generalizations.

Conclusion: Non-pharmacological interventions, particularly those targeting behavioral and psychological outcomes, improve QoL in dementia care. However, further high-quality studies with comprehensive outcome reporting are needed to strengthen the evidence base and guide populationspecific strategies.

Effect of Ascorbic Acid on the Transgenic Drosophila Expressing Human Aβ-42 in the Neurons

2026-04-16

Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by extracellular accumulation of amyloid-beta (Aβ) peptides, particularly the toxic Aβ42 isoform. Aβ42 aggregation induces excessive reactive oxygen species (ROS) production, resulting in oxidative damage, lipid peroxidation, protein oxidation, and neuronal dysfunction. Oxidative stress plays a pivotal role in AD pathogenesis, making antioxidants promising therapeutic candidates.

Objective: The present study aimed to evaluate the neuroprotective efficacy of ascorbic acid (AA), a potent dietary antioxidant, in a transgenic Drosophila melanogaster model of AD expressing human Aβ42 in neuronal tissues.

Materials and Methods: Transgenic Drosophila melanogaster expressing human Aβ42 under a neuronal driver were used as the AD model, with wild-type flies as controls. Flies were supplemented with optimized, non-toxic doses of AA throughout their lifespan. Oxidative stress and antioxidant defense were assessed using glutathione (GSH) levels, glutathione S-transferase (GST), thiobarbituric acid-reactive substances (TBARS), superoxide dismutase (SOD), catalase (CAT), protein carbonyl content (PCC), and acetylcholinesterase (AChE) activity. Locomotor performance was evaluated using the negative geotaxis assay.

Results: AA supplementation significantly restored redox homeostasis by increasing GSH levels and reducing TBARS and PCC. Antioxidant enzyme activities (GST, SOD, and CAT) were normalized, accompanied by partial restoration of AChE activity. AA-fed AD flies exhibited improved locomotor performance, delayed cognitive decline, and extended lifespan compared to untreated AD flies.

Discussion: The findings indicate that AA mitigates Aβ42-induced oxidative stress by enhancing endogenous antioxidant defenses and reducing oxidative damage. The improvement in AChE activity suggests preservation of cholinergic neurotransmission, which is crucial for learning and memory. Behavioral recovery and lifespan extension further demonstrate the systemic neuroprotective effects of AA, supporting its role as a multifunctional modulator of AD-associated pathology.

Conclusion: This study highlights the multidimensional neuroprotective potential of ascorbic acid in a transgenic Drosophila AD model. By alleviating oxidative stress, preserving cholinergic function, improving behavior, and promoting longevity, AA emerges as a promising, low-cost antioxidant for further evaluation in higher animal models and clinical settings.